Q1 FY27 results: revenue up 15%, PAT up 24%; director changes announced

Results View source PDF Explain this filing

GLAXO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.5%Reaction day

₹2655.00

prior close

₹2680.20

announcement price

After-mkt

timing

Nifty Midcap 150market-0.3%-0.2% vs market

Pharmaceuticals peers, median of 165sector+0.0%-0.5% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Midcap 150 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.4

10m

-2.0

15m

-1.9

30m

-1.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.5-0.3-0.2+0.0-0.5

Next day

-4.1-0.1-4.1+0.0-4.1

-2.8-0.5-2.4+0.2-3.0

-2.4-0.2-2.1+0.5-2.9

-2.1+0.2-2.3+0.6-2.7

-2.0+0.2-2.2+0.9-2.9

+0.2+0.5-0.3+0.6-0.4

15d

+13.3+0.5+12.8+0.5+12.8

+11.3-1.1+12.3+1.0+10.2

+3.0-7.1+10.1+2.0+1.0

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

GSK Pharma posted Q1 FY27 standalone revenue of Rs 924 crore, up 14.9% YoY. Standalone PAT rose 23.8% to Rs 253 crore. EPS at Rs 14.95 vs Rs 12.08. Consolidated revenue grew 16.6% to Rs 938 crore with PAT at Rs 237 crore. Director Subesh Williams stepped down; Karine Natland appointed as Non-Executive Director. Bhushan Akshikar re-appointed as MD for 2 years from 1 Dec 2026. Auditor Deloitte issued a clean review report.

Likely market impact

Strong Q1 with double-digit revenue and about 24% PAT growth, stable leadership. Positive for shareholders.